Highly potent and selective antagonist of the platelet P2Y1
= 0.78 nM). Inhibits ADP-induced aggregation of human platelets with an IC50
value of 0.95 nM. Inhibits the upregulation of NTPDase1 by ATPγ
S. Prevents thrombus formation in vivo
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold under license from the NIH, US Patent 10/169975
Stimulation of the P2Y1 receptor up-regulates nucleoside-triphosphate diphosphohydrolase-1 in human retinal pigment epithelial cells.
Lu et al.
2-Substitution of adenine nucleotide analogues containing a bicyclo[3.1.0]hexane ring system locked in a northern conformation: enhanced potency as P2Y1 receptor antagonists.
Kim et al.
Antiaggregatory activity in human platelets of potent antagonists of the P2Y1 receptor.
Cattaneo et al.
MRS2500 [2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3', 5'-bisphosphate], a potent, selective, and stable antagonist of the platelet P2Y1 receptor with strong antithrombotic activity in mice.
Hechler et al.
The citations listed below are publications that use Tocris products. Selected citations for MRS 2500 tetraammonium salt include:
Showing Results 1 - 10 of 15